Catalent (NYSE:CTLT) Announces Quarterly Earnings Results

Catalent (NYSE:CTLT) posted its earnings results on Wednesday. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of $0.21 by ($0.36), reports. The firm had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.11 billion. Catalent had a negative return on equity of 2.43% and a negative net margin of 29.91%.

Catalent Stock Performance

Shares of CTLT remained flat at $55.98 during midday trading on Friday. 421,223 shares of the stock were exchanged, compared to its average volume of 2,432,684. The stock has a market cap of $10.13 billion, a price-to-earnings ratio of -8.23, a PEG ratio of 6.09 and a beta of 1.18. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.73 and a current ratio of 2.48. The company’s 50 day simple moving average is $56.34 and its 200 day simple moving average is $49.36. Catalent has a 52 week low of $31.45 and a 52 week high of $60.20.

Institutional Trading of Catalent

Several hedge funds and other institutional investors have recently modified their holdings of CTLT. Lindbrook Capital LLC boosted its holdings in shares of Catalent by 79.4% during the 1st quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock worth $27,000 after buying an additional 208 shares during the period. Gladius Capital Management LP acquired a new position in shares of Catalent in the 3rd quarter valued at approximately $28,000. GAMMA Investing LLC acquired a new position in shares of Catalent in the 4th quarter valued at approximately $33,000. Cary Street Partners Investment Advisory LLC raised its position in shares of Catalent by 1,162.3% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 770 shares of the company’s stock valued at $35,000 after buying an additional 709 shares in the last quarter. Finally, Rakuten Securities Inc. acquired a new position in shares of Catalent in the 4th quarter valued at approximately $46,000.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. StockNews.com assumed coverage on shares of Catalent in a report on Sunday, May 5th. They issued a “sell” rating on the stock. UBS Group restated a “neutral” rating and set a $63.50 price objective (up from $58.00) on shares of Catalent in a report on Tuesday, February 6th. Stephens restated an “equal weight” rating and set a $63.50 price objective on shares of Catalent in a report on Thursday, April 4th. Barclays raised their price objective on shares of Catalent from $45.00 to $47.00 and gave the stock an “equal weight” rating in a report on Thursday, January 25th. Finally, Royal Bank of Canada restated a “sector perform” rating and set a $63.50 price objective on shares of Catalent in a report on Tuesday, February 20th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $52.46.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.